Cannabis sativa in Phytotherapy: Reappraisal of Therapeutic Potential and Regulatory Aspects


如何引用文章

全文:

详细

Cannabis sativa is widely used as a folk medicine in many parts of the globe and has been reported to be a treasure trove of phytoconstituents, including cannabinoids, terpenoids, and flavonoids. Accumulating evidence from various pre-clinical and clinical studies revealed the therapeutic potential of these constituents in various pathological conditions, including chronic pain, inflammation, neurological disorders, and cancer. However, the psychoactive effect and addiction potential associated with Cannabis use limited its clinical application. In the past two decades, extensive research on Cannabis has led to a resurgence of interest in the clinical application of its constituents, particularly cannabinoids. This review summarizes the therapeutic effect and molecular mechanism of various phytoconstituents of Cannabis. Furthermore, recently developed nanoformulations of Cannabis constituents have also been reviewed. Since Cannabis is often associated with illicit use, regulatory aspects are of vital importance and this review therefore also documented the regulatory aspects of Cannabis use along with clinical data and commercial products of Cannabis.

作者简介

Priya Gupta

Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard

Email: info@benthamscience.net

Archu Singh

Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard

Email: info@benthamscience.net

Sadat Shafi

Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard

Email: info@benthamscience.net

Tanya Ralli

Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard

Email: info@benthamscience.net

Faheem Pottoo

Department of Pharmacology, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University

Email: info@benthamscience.net

Yasmin Sultana

Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard

Email: info@benthamscience.net

Kanchan Kohli

Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard

编辑信件的主要联系方式.
Email: info@benthamscience.net

参考

  1. Bonini, S.A.; Premoli, M.; Tambaro, S.; Kumar, A.; Maccarinelli, G.; Memo, M.; Mastinu, A. Cannabis sativa: A comprehensive ethnopharmacological review of a medicinal plant with a long history. J. Ethnopharmacol., 2018, 227, 300-315. doi: 10.1016/j.jep.2018.09.004 PMID: 30205181
  2. Borille, B.T.; González, M.; Steffens, L.; Ortiz, R.S.; Limberger, R.P. Cannabis sativa: A systematic review of plant analysis. Drug Analytical Research, 2017, 1(1), 1-23. doi: 10.22456/2527-2616.73676
  3. Russo, E.B.; Jiang, H.E.; Li, X.; Sutton, A.; Carboni, A.; del Bianco, F.; Mandolino, G.; Potter, D.J.; Zhao, Y.X.; Bera, S.; Zhang, Y.B.; Lü, E.G.; Ferguson, D.K.; Hueber, F.; Zhao, L.C.; Liu, C.J.; Wang, Y.F.; Li, C.S. Phytochemical and genetic analyses of ancient Cannabis from Central Asia. J. Exp. Bot., 2008, 59(15), 4171-4182. doi: 10.1093/jxb/ern260 PMID: 19036842
  4. Wu, J. Cannabis, cannabinoid receptors, and endocannabinoid system: Yesterday, today, and tomorrow. Acta Pharmacol. Sin., 2019, 40(3), 297-299. doi: 10.1038/s41401-019-0210-3 PMID: 30670816
  5. Schofs, L.; Sparo, M.D.; Sánchez Bruni, S.F. The antimicrobial effect behind Cannabis sativa. Pharmacol. Res. Perspect., 2021, 9(2), e00761. doi: 10.1002/prp2.761 PMID: 33822478
  6. Andre, C.M.; Hausman, J.F.; Guerriero, G. Cannabis sativa: The plant of the thousand and one molecules. Front. Plant Sci., 2016, 7, 19. doi: 10.3389/fpls.2016.00019 PMID: 26870049
  7. Hartsel, J.A.; Eades, J.; Hickory, B.; Makriyannis, A. Cannabis sativa and Hemp. In: Nutraceuticals; Elsevier: Amsterdam, Netherlands, UK, 2016, pp. 735-754.
  8. Mechoulam, R. The pharmacohistory of Cannabis sativa. Cannabinoids as therapeutic agents; Chapman and Hall/CRC, 2019, pp. 1-20. doi: 10.1201/9780429260667
  9. Touw, M. The religious and medicinal uses of Cannabis in China, India and Tibet. J. Psychoactive Drugs, 1981, 13(1), 23-34. doi: 10.1080/02791072.1981.10471447 PMID: 7024492
  10. Zuardi, A.W. History of Cannabis as a medicine: A review. Rev. Bras. Psiquiatr., 2006, 28(2), 153-157. doi: 10.1590/S1516-44462006000200015 PMID: 16810401
  11. Crocq, M.A. History of Cannabis and the endocannabinoid system. Dialogues Clin. Neurosci., 2020, 22(3), 223-228. doi: 10.31887/DCNS.2020.22.3/mcrocq PMID: 33162765
  12. Bridgeman, M.B.; Abazia, D.T. Medicinal Cannabis: History, pharmacology, and implications for the acute care setting. P&T, 2017, 42(3), 180-188. PMID: 28250701
  13. Heilig, S. The pot book: A complete guide to Cannabis, its role in medicine, politics, science, and culture. J. Psychoactive Drugs, 2011, 43(1), 76-77. doi: 10.1080/02791072.2011.566505
  14. Musto, D.F. The marihuana tax act of 1937. Arch. Gen. Psychiatry, 1972, 26(2), 101-108. doi: 10.1001/archpsyc.1972.01750200005002 PMID: 4551255
  15. Iversen, L.L. The science of marijuana; Oxford University Press: United Kingdom, 2001.
  16. Izzo, A.A.; Borrelli, F.; Capasso, R.; Di Marzo, V.; Mechoulam, R. Non-psychotropic plant cannabinoids: New therapeutic opportunities from an ancient herb. Trends Pharmacol. Sci., 2009, 30(10), 515-527. doi: 10.1016/j.tips.2009.07.006 PMID: 19729208
  17. Pratt, M; Stevens, A; Thuku, M; Hutton, B; Wieland, S; Shea, B Protocol for a scoping review of systematic reviews: Benefits and harms of medical marijuana., 2018.
  18. Zou, S.; Kumar, U. Cannabinoid receptors and the endocannabinoid system: Signaling and function in the central nervous system. Int. J. Mol. Sci., 2018, 19(3), 833. doi: 10.3390/ijms19030833 PMID: 29533978
  19. Pellati, F.; Borgonetti, V.; Brighenti, V.; Biagi, M.; Benvenuti, S.; Corsi, L. Cannabis sativa L. and nonpsychoactive cannabinoids: Their chemistry and role against oxidative stress, inflammation, and cancer. BioMed Res. Int., 2018, 2018, 1691428.
  20. Kicman, A. Pędzińska-Betiuk, A.; Kozłowska, H. The potential of cannabinoids and inhibitors of endocannabinoid degradation in respiratory diseases. Eur. J. Pharmacol., 2021, 911, 174560. doi: 10.1016/j.ejphar.2021.174560 PMID: 34648805
  21. Hanuš, L.O. Pharmacological and therapeutic secrets of plant and brain (endo)cannabinoids. Med. Res. Rev., 2009, 29(2), 213-271. doi: 10.1002/med.20135 PMID: 18777572
  22. Hosking, R.D.; Zajicek, J.P. Therapeutic potential of Cannabis in pain medicine. Br. J. Anaesth., 2008, 101(1), 59-68. doi: 10.1093/bja/aen119 PMID: 18515270
  23. Hasan, N.; Imran, M.; Sheikh, A.; Saad, S.; Chaudhary, G.; Jain, G.K.; Kesharwani, P.; Ahmad, F.J. Cannabis as a potential compound against various malignancies, legal aspects, advancement by exploiting nanotechnology and clinical trials. J. Drug Target., 2022, 30(7), 709-725. doi: 10.1080/1061186X.2022.2056188 PMID: 35321629
  24. Pugazhendhi, A.; Suganthy, N.; Chau, T.P.; Sharma, A.; Unpaprom, Y.; Ramaraj, R.; Karuppusamy, I.; Brindhadevi, K. Cannabinoids as anticancer and neuroprotective drugs: Structural insights and pharmacological interactions—A review. Process Biochem., 2021, 111, 9-31. doi: 10.1016/j.procbio.2021.08.025
  25. Jiang, S.; Fu, Y.; Williams, J.; Wood, J.; Pandarinathan, L.; Avraham, S.; Makriyannis, A.; Avraham, S.; Avraham, H.K. Expression and function of cannabinoid receptors CB1 and CB2 and their cognate cannabinoid ligands in murine embryonic stem cells. PLoS One, 2007, 2(7), e641. doi: 10.1371/journal.pone.0000641 PMID: 17653268
  26. Deng, L.; Guindon, J.; Cornett, B.L.; Makriyannis, A.; Mackie, K.; Hohmann, A.G. Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal. Biol. Psychiatry, 2015, 77(5), 475-487. doi: 10.1016/j.biopsych.2014.04.009 PMID: 24853387
  27. Devane, W.A.; Hanuš, L.; Breuer, A.; Pertwee, R.G.; Stevenson, L.A.; Griffin, G.; Gibson, D.; Mandelbaum, A.; Etinger, A.; Mechoulam, R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 1992, 258(5090), 1946-1949. doi: 10.1126/science.1470919 PMID: 1470919
  28. Mechoulam, R.; Fride, E.; Di Marzo, V. Endocannabinoids. Eur. J. Pharmacol., 1998, 359(1), 1-18. doi: 10.1016/S0014-2999(98)00649-9 PMID: 9831287
  29. Pertwee, R.G. The pharmacology of cannabinoid receptors and their ligands: An overview. Int. J. Obes., 2006, 30(S1)(Suppl. 1), S13-S18. doi: 10.1038/sj.ijo.0803272 PMID: 16570099
  30. Di Marzo, V.; Bisogno, T.; De Petrocellis, L. Endocannabinoids and related compounds: Walking back and forth between plant natural products and animal physiology. Chem. Biol., 2007, 14(7), 741-756. doi: 10.1016/j.chembiol.2007.05.014 PMID: 17656311
  31. Di Marzo, V.; Petrosino, S. Endocannabinoids and the regulation of their levels in health and disease. Curr. Opin. Lipidol., 2007, 18(2), 129-140. doi: 10.1097/MOL.0b013e32803dbdec PMID: 17353660
  32. Radwan, M.M.; Wanas, A.S.; Chandra, S.; ElSohly, M.A. Natural cannabinoids of Cannabis and methods of analysis. Cannabis sativa l-botany and biotechnology; Springer: Cham, 2017, pp. 161-182. doi: 10.1007/978-3-319-54564-6_7
  33. Hill, A.J.; Williams, C.M.; Whalley, B.J.; Stephens, G.J. Phytocannabinoids as novel therapeutic agents in CNS disorders. Pharmacol. Ther., 2012, 133(1), 79-97. doi: 10.1016/j.pharmthera.2011.09.002 PMID: 21924288
  34. Pertwee, R.G. The diverse CB 1 and CB 2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. Br. J. Pharmacol., 2008, 153(2), 199-215. doi: 10.1038/sj.bjp.0707442 PMID: 17828291
  35. Russo, E.B. Taming THC: Potential Cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br. J. Pharmacol., 2011, 163(7), 1344-1364. doi: 10.1111/j.1476-5381.2011.01238.x PMID: 21749363
  36. Razdan, R.K. Structure-activity relationships in cannabinoids. Pharmacol. Rev., 1986, 3(2), 75-149.
  37. Hollister, L.E.; Gillespie, H.K. Delta-8- and delta-9-tetrahydrocannabinol; Comparison in man by oral and intravenous administration. Clin. Pharmacol. Ther., 1973, 14(3), 353-357. doi: 10.1002/cpt1973143353 PMID: 4698563
  38. Abrahamov, A.; Abrahamov, A.; Mechoulam, R. An efficient new cannabinoid antiemetic in pediatric oncology. Life Sci., 1995, 56(23-24), 2097-2102. doi: 10.1016/0024-3205(95)00194-B PMID: 7776837
  39. ClinicalTrials.gov Search Results. 2021. Available From: https://clinicaltrials.gov/
  40. Consroe, P.; Wolkin, A. Cannabidiol-antiepileptic drug comparisons and interactions in experimentally induced seizures in rats. J. Pharmacol. Exp. Ther., 1977, 201(1), 26-32. PMID: 850145
  41. Cunha, J.M.; Carlini, E.A.; Pereira, A.E.; Ramos, O.L.; Pimentel, C.; Gagliardi, R.; Sanvito, W.L.; Lander, N.; Mechoulam, R. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology, 1980, 21(3), 175-185. doi: 10.1159/000137430 PMID: 7413719
  42. Trembly, B.; Sherman, M. Double-blind clinical study of cannabidiol as a secondary anticonvulsant. Marijuana '90 International Conference on Cannabis and Cannabinoids., Kolympari, Crete. International Association for Cannabinoid Medicines, 1990.
  43. Zuardi, A.; Guimaraes, F.; Moreira, A. Effect of cannabidiol on plasma prolactin, growth hormone and cortisol in human volunteers. Brazilian journal of medical biological research. Rev. Bras. Pesqui. Med. Biol., 1993, 26(2), 213-217.
  44. Ligresti, A.; Moriello, A.S.; Starowicz, K.; Matias, I.; Pisanti, S.; De Petrocellis, L.; Laezza, C.; Portella, G.; Bifulco, M.; Di Marzo, V. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J. Pharmacol. Exp. Ther., 2006, 318(3), 1375-1387. doi: 10.1124/jpet.106.105247 PMID: 16728591
  45. Appendino, G.; Gibbons, S.; Giana, A.; Pagani, A.; Grassi, G.; Stavri, M.; Smith, E.; Rahman, M.M. Antibacterial cannabinoids from Cannabis sativa: A structure-activity study. J. Nat. Prod., 2008, 71(8), 1427-1430. doi: 10.1021/np8002673 PMID: 18681481
  46. Mastinu, A.; Premoli, M.; Ferrari-Toninelli, G.; Tambaro, S.; Maccarinelli, G.; Memo, M.; Bonini, S.A. Cannabinoids in health and disease: Pharmacological potential in metabolic syndrome and neuroinflammation. Horm. Mol. Biol. Clin. Investig., 2018, 36(2), 20180013. doi: 10.1515/hmbci-2018-0013 PMID: 29601300
  47. Lim, K.; See, Y.M.; Lee, J. A systematic review of the effectiveness of medical Cannabis for psychiatric, movement and neurodegenerative disorders. Clin. Psychopharmacol. Neurosci., 2017, 15(4), 301-312. doi: 10.9758/cpn.2017.15.4.301 PMID: 29073741
  48. Devinsky, O.; Cilio, M.R.; Cross, H.; Fernandez-Ruiz, J.; French, J.; Hill, C.; Katz, R.; Di Marzo, V.; Jutras-Aswad, D.; Notcutt, W.G.; Martinez-Orgado, J.; Robson, P.J.; Rohrback, B.G.; Thiele, E.; Whalley, B.; Friedman, D. Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia, 2014, 55(6), 791-802. doi: 10.1111/epi.12631 PMID: 24854329
  49. Nigar, S.; Pottoo, F.H.; Tabassum, N.; Verma, S.K.; Javed, M.N. Molecular insights into the role of inflammation and oxidative stress in epilepsy. J Adv. Med. Pharm. Sci., 2016, 2016, 1-9. doi: 10.9734/JAMPS/2016/24441
  50. Fusar-Poli, P.; Crippa, J.A.; Bhattacharyya, S.; Borgwardt, S.J.; Allen, P.; Martin-Santos, R.; Seal, M.; Surguladze, S.A.; O’Carrol, C.; Atakan, Z.; Zuardi, A.W.; McGuire, P.K. Distinct effects of delta9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch. Gen. Psychiatry, 2009, 66(1), 95-105. doi: 10.1001/archgenpsychiatry.2008.519 PMID: 19124693
  51. Raucci, U.; Pietrafusa, N.; Paolino, M.C.; Di Nardo, G.; Villa, M.P.; Pavone, P.; Terrin, G.; Specchio, N.; Striano, P.; Parisi, P. Cannabidiol treatment for refractory epilepsies in pediatrics. Front. Pharmacol., 2020, 11(586110), 586110. doi: 10.3389/fphar.2020.586110 PMID: 33117180
  52. Anderson, L.L.; Low, I.K.; Banister, S.D.; McGregor, I.S.; Arnold, J.C. Pharmacokinetics of phytocannabinoid acids and anticonvulsant effect of cannabidiolic acid in a mouse model of dravet syndrome. J. Nat. Prod., 2019, 82(11), 3047-3055. doi: 10.1021/acs.jnatprod.9b00600 PMID: 31686510
  53. Carlini, E.A.; Leite, J.R.; Tannhauser, M.; Berardi, A.C. Cannabidiol and Cannabis sativa extract protect mice and rats against convulsive agents. J. Pharm. Pharmacol., 2011, 25(8), 664-665. doi: 10.1111/j.2042-7158.1973.tb10660.x PMID: 4148442
  54. Szaflarski, J.P.; Bebin, E.M.; Cutter, G.; DeWolfe, J.; Dure, L.S.; Gaston, T.E.; Kankirawatana, P.; Liu, Y.; Singh, R.; Standaert, D.G.; Thomas, A.E.; Ver Hoef, L.W. Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study. Epilepsy Behav., 2018, 87, 131-136. doi: 10.1016/j.yebeh.2018.07.020 PMID: 30100226
  55. Devinsky, O.; Marsh, E.; Friedman, D.; Thiele, E.; Laux, L.; Sullivan, J.; Miller, I.; Flamini, R.; Wilfong, A.; Filloux, F.; Wong, M.; Tilton, N.; Bruno, P.; Bluvstein, J.; Hedlund, J.; Kamens, R.; Maclean, J.; Nangia, S.; Singhal, N.S.; Wilson, C.A.; Patel, A.; Cilio, M.R. Cannabidiol in patients with treatment-resistant epilepsy: An open-label interventional trial. Lancet Neurol., 2016, 15(3), 270-278. doi: 10.1016/S1474-4422(15)00379-8 PMID: 26724101
  56. Aran, A; Cassuto, H Lubotzky, A Cannabidiol based medical Cannabis in children with autism- a retrospective feasibility study. (P3.318). Neurol., 2018, 90(15 Supplement)
  57. Sharma, P.; Sharma, A.; Fayaz, F.; Wakode, S.; Pottoo, F.H. Biological signatures of Alzheimer’s disease. Curr. Top. Med. Chem., 2020, 20(9), 770-781. doi: 10.2174/1568026620666200228095553 PMID: 32108008
  58. Mir, R.H.; Shah, A.J.; Mohi-Ud-Din, R.; Pottoo, F.H.; Dar, M.A.; Jachak, S.M.; Masoodi, M.H. Natural Anti-inflammatory compounds as Drug candidates in Alzheimer’s disease. Curr. Med. Chem., 2021, 28(23), 4799-4825. doi: 10.2174/1875533XMTA4aNzUBx PMID: 32744957
  59. Holgado, M.A.; Martín-Banderas, L.; Álvarez-Fuentes, J.; Fernández-Arévalo, M. Neuroprotective effect of cannabinoids nanoplatforms in neurodegenerative diseases. J. Drug Deliv. Sci. Technol., 2017, 42, 84-93. doi: 10.1016/j.jddst.2017.04.023
  60. Aso, E.; Ferrer, I. CB2 cannabinoid receptor as potential target against Alzheimer’s disease. Front. Neurosci., 2016, 10, 243. doi: 10.3389/fnins.2016.00243 PMID: 27303261
  61. Fernández-Ruiz, J. The biomedical challenge of neurodegenerative disorders: An opportunity for cannabinoid-based therapies to improve on the poor current therapeutic outcomes. Br. J. Pharmacol., 2019, 176(10), 1370-1383. doi: 10.1111/bph.14382 PMID: 29856067
  62. Patton, G.C.; Coffey, C.; Carlin, J.B.; Degenhardt, L.; Lynskey, M.; Hall, W. Cannabis use and mental health in young people: Cohort study. BMJ, 2002, 325(7374), 1195-1198. doi: 10.1136/bmj.325.7374.1195 PMID: 12446533
  63. Suliman, N.A.; Taib, C.N.M.; Moklas, M.A.M.; Basir, R. Delta-9-Tetrahydrocannabinol (∆9-THC) induce neurogenesis and improve cognitive performances of male sprague dawley rats. Neurotox. Res., 2018, 33(2), 402-411. doi: 10.1007/s12640-017-9806-x PMID: 28933048
  64. Bilkei-Gorzo, A.; Albayram, O.; Draffehn, A.; Michel, K.; Piyanova, A.; Oppenheimer, H.; Dvir-Ginzberg, M.; Rácz, I.; Ulas, T.; Imbeault, S.; Bab, I.; Schultze, J.L.; Zimmer, A. A chronic low dose of Δ9-tetrahydrocannabinol (THC) restores cognitive function in old mice. Nat. Med., 2017, 23(6), 782-787. doi: 10.1038/nm.4311 PMID: 28481360
  65. Aso, E.; Juvés, S.; Maldonado, R.; Ferrer, I. CB2 cannabinoid receptor agonist ameliorates Alzheimer-like phenotype in AβPP/PS1 mice. J. Alzheimers Dis., 2013, 35(4), 847-858. doi: 10.3233/JAD-130137 PMID: 23515018
  66. Walther, S.; Mahlberg, R.; Eichmann, U.; Kunz, D. Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacology (Berl.), 2006, 185(4), 524-528. doi: 10.1007/s00213-006-0343-1 PMID: 16521031
  67. Esposito, G.; Scuderi, C.; Savani, C.; Steardo, L., Jr; De Filippis, D.; Cottone, P.; Iuvone, T.; Cuomo, V.; Steardo, L. Cannabidiol in vivo blunts β-amyloid induced neuroinflammation by suppressing IL-1β and iNOS expression. Br. J. Pharmacol., 2007, 151(8), 1272-1279. doi: 10.1038/sj.bjp.0707337 PMID: 17592514
  68. Shelef, A.; Barak, Y.; Berger, U.; Paleacu, D.; Tadger, S.; Plopsky, I.; Baruch, Y. Safety and efficacy of medical Cannabis oil for behavioral and psychological symptoms of dementia: An-open label, add-on, pilot study. J. Alzheimers Dis., 2016, 51(1), 15-19. doi: 10.3233/JAD-150915 PMID: 26757043
  69. Eggers, C.; Fujitani, M.; Kato, R.; Smid, S. Novel Cannabis flavonoid, cannflavin A displays both a hormetic and neuroprotective profile against amyloid β-mediated neurotoxicity in PC12 cells: Comparison with geranylated flavonoids, mimulone and diplacone. Biochem. Pharmacol., 2019, 169, 113609. doi: 10.1016/j.bcp.2019.08.011 PMID: 31437460
  70. Franke, T.; Irwin, C.; Beindorff, N.; Bouter, Y.; Bouter, C. Effects of tetrahydrocannabinol treatment on brain metabolism and neuron loss in a mouse model of sporadic Alzheimer’s disease. Nucl. Med., 2019, 58(02), 94.
  71. Kumar, B.; Pandey, M.; Fayaz, F.; Izneid, T.A.; Pottoo, F.H.; Manchanda, S.; Sharma, A.; Sahoo, P.K. Applications of Exosomes in targeted drug delivery for the treatment of Parkinson’s Disease: A review of recent advances and clinical challenges. Curr. Top. Med. Chem., 2020, 20(30), 2777-2788. doi: 10.2174/1568026620666201019112557 PMID: 33076810
  72. Sharma, S.; Rabbani, S.A.; Agarwal, T.; Baboota, S.; Pottoo, F.H.; Kadian, R. Nanotechnology driven approaches for the management of Parkinson’s Dis-ease: Current status and future perspectives. Curr. Drug Metab., 2021, 22(4), 287-298. doi: 10.2174/18755453MTExhNzY00 PMID: 33234098
  73. Köfalvi, A. Alternative interacting sites and novel receptors for cannabinoid ligands. Cannabinoids and the brain; Springer: Cham, 2008, pp. 131-160.
  74. García, C.; Palomo-Garo, C.; García-Arencibia, M.; Ramos, J.A.; Pertwee, R.G.; Fernández-Ruiz, J. Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ9-THCV in animal models of Parkinson’s disease. Br. J. Pharmacol., 2011, 163(7), 1495-1506. doi: 10.1111/j.1476-5381.2011.01278.x PMID: 21323909
  75. Lastres-Becker, I.; Molina-Holgado, F.; Ramos, J.A.; Mechoulam, R.; Fernández-Ruiz, J. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: Relevance to Parkinson’s disease. Neurobiol. Dis., 2005, 19(1-2), 96-107. doi: 10.1016/j.nbd.2004.11.009 PMID: 15837565
  76. Gonçalves, J.; Rosado, T.; Soares, S.; Simão, A.; Caramelo, D.; Luís, .; Fernández, N.; Barroso, M.; Gallardo, E.; Duarte, A. Cannabis and its secondary metabolites: Their use as therapeutic drugs, toxicological aspects, and analytical determination. Medicines, 2019, 6(1), 31. doi: 10.3390/medicines6010031 PMID: 30813390
  77. Peres, F.F.; Levin, R.; Suiama, M.A.; Diana, M.C.; Gouvêa, D.A.; Almeida, V.; Santos, C.M.; Lungato, L.; Zuardi, A.W.; Hallak, J.E.C.; Crippa, J.A.; Vânia, D.A.; Silva, R.H.; Abílio, V.C. Cannabidiol prevents motor and cognitive impairments induced by reserpine in rats. Front. Pharmacol., 2016, 7, 343. doi: 10.3389/fphar.2016.00343 PMID: 27733830
  78. Consroe, P.; Sandyk, R.; Snider, S.R. Open label evaluation of cannabidiol in dystonic movement disorders. Int. J. Neurosci., 1986, 30(4), 277-282. doi: 10.3109/00207458608985678 PMID: 3793381
  79. Zuardi, A.W.; Crippa, J.; Hallak, J.E.C.; Pinto, J.P.; Chagas, M.H.N.; Rodrigues, G.G.R.; Dursun, S.M.; Tumas, V. Cannabidiol for the treatment of psychosis in Parkinson’s disease. J. Psychopharmacol., 2009, 23(8), 979-983. doi: 10.1177/0269881108096519 PMID: 18801821
  80. Kumar, S.; Singh, P.; Sharma, S.; Ali, J.; Baboota, S.; Pottoo, F.H. Proteomic analysis of Huntington’s Disease. Curr. Protein Pept. Sci., 2020, 21(12), 1218-1222. doi: 10.2174/1389203721666201006160327 PMID: 33023443
  81. Muñoz-Rubio, I.; Cózar-Bernal, M.; Álvarez-Fuentes, J.; Martín-Banderas, L.; Fernández-Arévalo, M.; Holgado, M.J.I.F. Aplicaciones de los cannabinoides como agentes terapéuticos. Gac. Med. Mex., 2011, 163, 68-77.
  82. Blázquez, C.; Chiarlone, A.; Sagredo, O.; Aguado, T.; Pazos, M.R.; Resel, E.; Palazuelos, J.; Julien, B.; Salazar, M.; Börner, C.; Benito, C.; Carrasco, C.; Diez-Zaera, M.; Paoletti, P.; Díaz-Hernández, M.; Ruiz, C.; Sendtner, M.; Lucas, J.J.; de Yébenes, J.G.; Marsicano, G.; Monory, K.; Lutz, B.; Romero, J.; Alberch, J.; Ginés, S.; Kraus, J.; Fernández-Ruiz, J.; Galve-Roperh, I.; Guzmán, M. Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington’s disease. Brain, 2011, 134(1), 119-136. doi: 10.1093/brain/awq278 PMID: 20929960
  83. Abdel-Salam, O. Cannabis for Basal Ganglia Disorders (Parkinson Disease and Huntington Disease). In: Handbook of Cannabis and Related Pathologies; Elsevier: Amsterdam, Netherlands, 2017, pp. 917-930.
  84. Sandyk, R.; Consroe, P.; Stern, L.; Snider, S. Effects of cannabidiol in Huntington’s disease. Neurology, 1986, 36(Suppl. 1), 342.
  85. Consroe, P.; Laguna, J.; Allender, J.; Snider, S.; Stern, L.; Sandyk, R.; Kennedy, K.; Schram, K. Controlled clinical trial of cannabidiol in Huntington’s disease. Pharmacol. Biochem. Behav., 1991, 40(3), 701-708. doi: 10.1016/0091-3057(91)90386-G PMID: 1839644
  86. Curtis, A.; Mitchell, I.; Patel, S.; Ives, N.; Rickards, H. A pilot study using nabilone for symptomatic treatment in Huntington’s disease. Mov. Disord., 2009, 24(15), 2254-2259. doi: 10.1002/mds.22809 PMID: 19845035
  87. López-Sendón Moreno, J.L.; García Caldentey, J.; Trigo Cubillo, P.; Ruiz Romero, C.; García Ribas, G.; Alonso Arias, M.A.A.; García de Yébenes, M.J.; Tolón, R.M.; Galve-Roperh, I.; Sagredo, O.; Valdeolivas, S.; Resel, E.; Ortega-Gutierrez, S.; García-Bermejo, M.L.; Fernández Ruiz, J.; Guzmán, M.; García de Yébenes Prous, J. A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington’s disease. J. Neurol., 2016, 263(7), 1390-1400. doi: 10.1007/s00415-016-8145-9 PMID: 27159993
  88. Chayasirisobhon, S. Cannabis and Neuropsychiatric Disorders: An Updated Review. Acta Neurol. Taiwan., 2019, 28(2), 27-39. PMID: 31867704
  89. Whiting, P.F.; Wolff, R.F.; Deshpande, S.; Di Nisio, M.; Duffy, S.; Hernandez, A.V.; Keurentjes, J.C.; Lang, S.; Misso, K.; Ryder, S.; Schmidlkofer, S.; Westwood, M.; Kleijnen, J. Cannabinoids for medical use: A systematic review and meta-analysis. JAMA, 2015, 313(24), 2456-2473. doi: 10.1001/jama.2015.6358 PMID: 26103030
  90. Lee, J.L.C.; Bertoglio, L.J.; Guimarães, F.S.; Stevenson, C.W. Cannabidiol regulation of emotion and emotional memory processing: Relevance for treating anxiety-related and substance abuse disorders. Br. J. Pharmacol., 2017, 174(19), 3242-3256. doi: 10.1111/bph.13724 PMID: 28268256
  91. Campos, A.C.; Guimarães, F.S. Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats. Psychopharmacology, 2008, 199(2), 223-230. doi: 10.1007/s00213-008-1168-x PMID: 18446323
  92. Bisogno, T.; Hanuš, L.; De Petrocellis, L.; Tchilibon, S.; Ponde, D.E.; Brandi, I.; Moriello, A.S.; Davis, J.B.; Mechoulam, R.; Di Marzo, V. Molecular targets for cannabidiol and its synthetic analogues: Effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br. J. Pharmacol., 2001, 134(4), 845-852. doi: 10.1038/sj.bjp.0704327 PMID: 11606325
  93. Papagianni, E.P.; Stevenson, C.W. Cannabinoid regulation of fear and anxiety: An update. Curr. Psychiatry Rep., 2019, 21(6), 38. doi: 10.1007/s11920-019-1026-z PMID: 31030284
  94. Namdar, D.; Koltai, H. Medical Cannabis for the treatment of inflammation. Nat. Prod. Commun., 2018, 13(3), 1-6. doi: 10.1177/1934578X1801300304
  95. Atalay, S.; Jarocka-Karpowicz, I.; Skrzydlewska, E. Antioxidative and anti-inflammatory properties of Cannabidiol. Antioxidants, 2019, 9(1), 21. doi: 10.3390/antiox9010021 PMID: 31881765
  96. Burstein, S. Cannabidiol (CBD) and its analogs: A review of their effects on inflammation. Bioorg. Med. Chem., 2015, 23(7), 1377-1385. doi: 10.1016/j.bmc.2015.01.059 PMID: 25703248
  97. Jamontt, J.M.; Molleman, A.; Pertwee, R.G.; Parsons, M.E. The effects of Δ9-tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis. Br. J. Pharmacol., 2010, 160(3), 712-723. doi: 10.1111/j.1476-5381.2010.00791.x PMID: 20590574
  98. Costa, B.; Colleoni, M.; Conti, S.; Parolaro, D.; Franke, C.; Trovato, A.E.; Giagnoni, G. Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of Cannabis, in acute carrageenan-induced inflammation in the rat paw. Naunyn Schmiedebergs Arch. Pharmacol., 2004, 369(3), 294-299. doi: 10.1007/s00210-004-0871-3 PMID: 14963641
  99. Ben-Shabat, S.; Hanuš, L.O.; Katzavian, G.; Gallily, R. New cannabidiol derivatives: Synthesis, binding to cannabinoid receptor, and evaluation of their antiinflammatory activity. J. Med. Chem., 2006, 49(3), 1113-1117. doi: 10.1021/jm050709m PMID: 16451075
  100. Petrosino, S.; Verde, R.; Vaia, M.; Allarà, M.; Iuvone, T.; Di Marzo, V. Anti-inflammatory properties of cannabidiol, a nonpsychotropic cannabinoid, in experimental allergic contact dermatitis. J. Pharmacol. Exp. Ther., 2018, 365(3), 652-663. doi: 10.1124/jpet.117.244368 PMID: 29632236
  101. Borges, R.; Batista, J., Jr; Viana, R.; Baetas, A.; Orestes, E.; Andrade, M.; Honório, K.; da Silva, A. Understanding the molecular aspects of tetrahydrocannabinol and cannabidiol as antioxidants. Molecules, 2013, 18(10), 12663-12674. doi: 10.3390/molecules181012663 PMID: 24129275
  102. Pan, H.; Mukhopadhyay, P.; Rajesh, M.; Patel, V.; Mukhopadhyay, B.; Gao, B.; Haskó, G.; Pacher, P. Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death. J. Pharmacol. Exp. Ther., 2009, 328(3), 708-714. doi: 10.1124/jpet.108.147181 PMID: 19074681
  103. Fouad, A.A.; Albuali, W.H.; Al-Mulhim, A.S.; Jresat, I. Cardioprotective effect of cannabidiol in rats exposed to doxorubicin toxicity. Environ. Toxicol. Pharmacol., 2013, 36(2), 347-357. doi: 10.1016/j.etap.2013.04.018 PMID: 23721741
  104. Blanchard, D.K.; Newton, C.; Klein, T.W.; Stewart, W.E., II; Friedman, H. In vitro and in vivo suppressive effects of delta-9-tetrahydrocannabinol on interferon production by murine spleen cells. Int. J. Immunopharmacol., 1986, 8(7), 819-824. doi: 10.1016/0192-0561(86)90020-2 PMID: 2430904
  105. Cabral, G.A.; Lockmuller, J.C.; Mishkin, E.M. Delta 9-tetrahydrocannabinol decreases alpha/beta interferon response to herpes simplex virus type 2 in the B6C3F1 mouse. Exp. Biol. Med., 1986, 181(2), 305-311. doi: 10.3181/00379727-181-42258 PMID: 3003756
  106. Gaffal, E.; Cron, M.; Glodde, N.; Tüting, T. Anti-inflammatory activity of topical THC in DNFB-mediated mouse allergic contact dermatitis independent of CB1 and CB2 receptors. Allergy, 2013, 68(8), 994-1000. doi: 10.1111/all.12183 PMID: 23889474
  107. Hampson, A.J.; Grimaldi, M.; Axelrod, J.; Wink, D. Cannabidiol and (−)Δ9-tetrahydrocannabinol are neuroprotective antioxidants. Proc. Natl. Acad. Sci. USA, 1998, 95(14), 8268-8273. doi: 10.1073/pnas.95.14.8268 PMID: 9653176
  108. Chen, J.; Errico, S.L.; Freed, W.J. Reactive oxygen species and p38 phosphorylation regulate the protective effect of Δ9-tetrahydrocannabinol in the apoptotic response to NMDA. Neurosci. Lett., 2005, 389(2), 99-103. doi: 10.1016/j.neulet.2005.07.028 PMID: 16098661
  109. Perez, E.; Fernandez, J.R.; Fitzgerald, C.; Rouzard, K.; Tamura, M.; Savile, C. In vitro and clinical evaluation of cannabigerol (CBG) produced via yeast biosynthesis: A Cannabinoid with a broad range of anti-inflammatory and skin health-boosting properties. Molecules, 2022, 27(2), 491. doi: 10.3390/molecules27020491 PMID: 35056807
  110. Borrelli, F.; Fasolino, I.; Romano, B.; Capasso, R.; Maiello, F.; Coppola, D.; Orlando, P.; Battista, G.; Pagano, E.; Di Marzo, V.; Izzo, A.A. Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochem. Pharmacol., 2013, 85(9), 1306-1316. doi: 10.1016/j.bcp.2013.01.017 PMID: 23415610
  111. Flachenecker, P.; Henze, T.; Zettl, U.K. Spasticity in patients with multiple sclerosis - clinical characteristics, treatment and quality of life. Acta Neurol. Scand., 2014, 129(3), 154-162. doi: 10.1111/ane.12202 PMID: 24256407
  112. Soelberg Sorensen, P. Safety concerns and risk management of multiple sclerosis therapies. Acta Neurol. Scand., 2017, 136(3), 168-186. doi: 10.1111/ane.12712 PMID: 27891572
  113. Gilman, S.; Newman, S.W.; Manter, J.T. Manter and Gatz’s essentials of clinical neuroanatomy and neurophysiology; FA Davis Company: Philadelphia, 1996.
  114. Śmiarowska, M.; Białecka, M.; Machoy-Mokrzyńska, A. Cannabis and cannabinoids: Pharmacology and therapeutic potential. Neurol Neurochir Pol., 2022, 56(1), 4-13.
  115. Pertwee, R.G. Sites and mechanisms of action. In: Pharmacol. Toxicol. Ther. Potent; Haworth Press: New York, 2002, pp. 73-87.
  116. Koppel, B.S.; Brust, J.C.M.; Fife, T.; Bronstein, J.; Youssof, S.; Gronseth, G.; Gloss, D. Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology, 2014, 82(17), 1556-1563. doi: 10.1212/WNL.0000000000000363 PMID: 24778283
  117. Nielsen, S.; Germanos, R.; Weier, M.; Pollard, J.; Degenhardt, L.; Hall, W.; Buckley, N.; Farrell, M. The use of Cannabis and cannabinoids in treating symptoms of multiple sclerosis: A systematic review of reviews. Curr. Neurol. Neurosci. Rep., 2018, 18(2), 8. doi: 10.1007/s11910-018-0814-x PMID: 29442178
  118. Allan, G.M.; Finley, C.R.; Ton, J.; Perry, D.; Ramji, J.; Crawford, K.; Lindblad, A.J.; Korownyk, C.; Kolber, M.R. Systematic review of systematic reviews for medical cannabinoids: Pain, nausea and vomiting, spasticity, and harms. Can. Fam. Physician, 2018, 64(2), e78-e94. PMID: 29449262
  119. Baker, D.; Pryce, G.; Croxford, J.L.; Brown, P.; Pertwee, R.G.; Huffman, J.W.; Layward, L. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature, 2000, 404(6773), 84-87. doi: 10.1038/35003583 PMID: 10716447
  120. Keating, G.M. Delta-9-tetrahydrocannabinol/cannabidiol oromucosal spray (Sativex®): A review in multiple sclerosis-related spasticity. Drugs, 2017, 77(5), 563-574. doi: 10.1007/s40265-017-0720-6 PMID: 28293911
  121. Pavisian, B.; MacIntosh, B.J.; Szilagyi, G.; Staines, R.W.; O’Connor, P.; Feinstein, A. Effects of Cannabis on cognition in patients with MS: A psychometric and MRI study. Neurology, 2014, 82(21), 1879-1887. doi: 10.1212/WNL.0000000000000446 PMID: 24789863
  122. Rudroff, T.; Honce, J.M. Cannabis and multiple sclerosis—the way forward. Front. Neurol., 2017, 8, 299. doi: 10.3389/fneur.2017.00299 PMID: 28690588
  123. Rice, J.; Cameron, M. Cannabinoids for treatment of MS symptoms: State of the evidence. Curr. Neurol. Neurosci. Rep., 2018, 18(8), 50. doi: 10.1007/s11910-018-0859-x PMID: 29923025
  124. Herzog, S.; Shanahan, M.; Grimison, P.; Tran, A.; Wong, N.; Lintzeris, N.; Simes, J.; Stockler, M.; Morton, R.L. Systematic review of the costs and benefits of prescribed Cannabis-based medicines for the management of chronic illness: Lessons from multiple sclerosis. PharmacoEconomics, 2018, 36(1), 67-78. doi: 10.1007/s40273-017-0565-6 PMID: 28866778
  125. Malfitano, A.M.; Proto, M.C.; Bifulco, M. Cannabinoids in the management of spasticity associated with multiple sclerosis. Neuropsychiatr. Dis. Treat., 2008, 4(5), 847-853. PMID: 19183777
  126. Dariš, B.; Tancer Verboten, M.; Knez, Ž.; Ferk, P. Cannabinoids in cancer treatment: Therapeutic potential and legislation. Bosn. J. Basic Med. Sci., 2019, 19(1), 14-23. doi: 10.17305/bjbms.2018.3532 PMID: 30172249
  127. McAllister, S.D.; Soroceanu, L.; Desprez, P.Y. The antitumor activity of plant-derived non-psychoactive cannabinoids. J. Neuroimmune Pharmacol., 2015, 10(2), 255-267. doi: 10.1007/s11481-015-9608-y PMID: 25916739
  128. Velasco, G.; Sánchez, C.; Guzmán, M. Anticancer mechanisms of cannabinoids. Curr. Oncol., 2016, 23(11), 23-32. doi: 10.3747/co.23.3080 PMID: 27022311
  129. Cridge, B.J.; Rosengren, R.J. Critical appraisal of the potential use of cannabinoids in cancer management. Cancer Manag. Res., 2013, 5, 301-313. PMID: 24039449
  130. Hart, S.; Fischer, O.M.; Ullrich, A. Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. Cancer Res., 2004, 64(6), 1943-1950. doi: 10.1158/0008-5472.CAN-03-3720 PMID: 15026328
  131. Sharma, M.; Hudson, J.B.; Adomat, H.; Guns, E.; Cox, M.E. in vitro anticancer activity of plant-derived cannabidiol on prostate cancer cell lines. Pharmacol. Pharm., 2014, 5(8), 806-820. doi: 10.4236/pp.2014.58091
  132. Shrivastava, A.; Kuzontkoski, P.M.; Groopman, J.E.; Prasad, A. Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy. Mol. Cancer Ther., 2011, 10(7), 1161-1172. doi: 10.1158/1535-7163.MCT-10-1100 PMID: 21566064
  133. Solinas, M.; Massi, P.; Cinquina, V.; Valenti, M.; Bolognini, D.; Gariboldi, M.; Monti, E.; Rubino, T.; Parolaro, D. Cannabidiol, a non-psychoactive cannabinoid compound, inhibits proliferation and invasion in U87-MG and T98G glioma cells through a multitarget effect. PLoS One, 2013, 8(10), e76918. doi: 10.1371/journal.pone.0076918 PMID: 24204703
  134. Takeda, S.; Misawa, K.; Yamamoto, I.; Watanabe, K. Cannabidiolic acid as a selective cyclooxygenase-2 inhibitory component in Cannabis. Drug Metab. Dispos., 2008, 36(9), 1917-1921. doi: 10.1124/dmd.108.020909 PMID: 18556441
  135. Grimaldi, C.; Pisanti, S.; Laezza, C.; Malfitano, A.M.; Santoro, A.; Vitale, M.; Caruso, M.G.; Notarnicola, M.; Iacuzzo, I.; Portella, G.; Di Marzo, V.; Bifulco, M. Anandamide inhibits adhesion and migration of breast cancer cells. Exp. Cell Res., 2006, 312(4), 363-373. doi: 10.1016/j.yexcr.2005.10.024 PMID: 16343481
  136. Hussein, N.A.E.M.; El-Toukhy, M.A.E.F.; Kazem, A.H.; Ali, M.E.S.; Ahmad, M.A.E.R.; Ghazy, H.M.R.; El-Din, A.M.G. Protective and therapeutic effects of Cannabis plant extract on liver cancer induced by dimethylnitrosamine in mice. Alex. J. Med., 2014, 50(3), 241-251. doi: 10.1016/j.ajme.2014.02.003
  137. Hernán Pérez de la Ossa, D.; Lorente, M.; Gil-Alegre, M.E.; Torres, S.; García-Taboada, E.; Aberturas, M.R.; Molpeceres, J.; Velasco, G.; Torres-Suárez, A.I. Local delivery of cannabinoid-loaded microparticles inhibits tumor growth in a murine xenograft model of glioblastoma multiforme. PLoS One, 2013, 8(1), e54795. doi: 10.1371/journal.pone.0054795 PMID: 23349970
  138. Romano, B.; Pagano, E.; Orlando, P.; Capasso, R.; Cascio, M.G.; Pertwee, R.; Marzo, V.D.; Izzo, A.A.; Borrelli, F. Pure Δ 9 - tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ 9 -tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages. Pharmacol. Res., 2016, 113(Pt A), 199-208. doi: 10.1016/j.phrs.2016.07.045 PMID: 27498155
  139. Reiss, C.S. Cannabinoids and Viral Infections. Pharmaceuticals, 2010, 3(6), 1873-1886. doi: 10.3390/ph3061873 PMID: 20634917
  140. Campos, A.C.; Brant, F.; Miranda, A.S.; Machado, F.S.; Teixeira, A.L. Cannabidiol increases survival and promotes rescue of cognitive function in a murine model of cerebral malaria. Neuroscience, 2015, 289, 166-180. doi: 10.1016/j.neuroscience.2014.12.051 PMID: 25595981
  141. Meza, A.; Lehmann, C. Betacaryophyllene – A phytocannabinoid as potential therapeutic modality for human sepsis? Med. Hypotheses, 2018, 110, 68-70. doi: 10.1016/j.mehy.2017.10.025 PMID: 29317072
  142. Mulpuri, Y.; Marty, V.N.; Munier, J.J.; Mackie, K.; Schmidt, B.L.; Seltzman, H.H.; Spigelman, I. Synthetic peripherally-restricted cannabinoid suppresses chemotherapy-induced peripheral neuropathy pain symptoms by CB1 receptor activation. Neuropharmacology, 2018, 139, 85-97. doi: 10.1016/j.neuropharm.2018.07.002 PMID: 29981335
  143. Vučković S.; Srebro, D.; Vujović K.S.; Vučetić Č Prostran, M. Cannabinoids and pain: New insights from old molecules. Front. Pharmacol., 2018, 9, 1259. doi: 10.3389/fphar.2018.01259 PMID: 30542280
  144. Davis, M.P. Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands. Expert Opin. Investig. Drugs, 2014, 23(8), 1123-1140. doi: 10.1517/13543784.2014.918603 PMID: 24836296
  145. Starowicz, K.; Finn, D.P. Cannabinoids and pain: Sites and mechanisms of action. Adv. Pharmacol., 2017, 80, 437-475. doi: 10.1016/bs.apha.2017.05.003 PMID: 28826543
  146. Sharkey, K.A.; Darmani, N.A.; Parker, L.A. Regulation of nausea and vomiting by cannabinoids and the endocannabinoid system. Eur. J. Pharmacol., 2014, 722, 134-146. doi: 10.1016/j.ejphar.2013.09.068 PMID: 24184696
  147. Taylor, B.N.; Mueller, M.; Sauls, R.S. Cannaboinoid antiemetic therapy; StatPearls: Florida, 2018.
  148. Parker, L.A.; Kemp, S.W.P. Tetrahydrocannabinol (THC) interferes with conditioned retching in Suncus murinus: An animal model of anticipatory nausea and vomiting (ANV). Neuroreport, 2001, 12(4), 749-751. doi: 10.1097/00001756-200103260-00027 PMID: 11277577
  149. Badowski, M.E. A review of oral cannabinoids and medical marijuana for the treatment of chemotherapy-induced nausea and vomiting: A focus on pharmacokinetic variability and pharmacodynamics. Cancer Chemother. Pharmacol., 2017, 80(3), 441-449. doi: 10.1007/s00280-017-3387-5 PMID: 28780725
  150. Cardiol Therapeutics Receives FDA Approval for Investigational New Drug (IND) Application for Phase II/III COVID-19 Trial. 2020. Available From: https://www.cardiolrx.com/cardiol-therapeutics-receives-fda-approval-for-investigational-new-drug-ind-application-for-phase-ii-iii-covid-19-trial/
  151. Coughlin, L.N.; Ilgen, M.A.; Jannausch, M.; Walton, M.A.; Bohnert, K.M. Progression of Cannabis withdrawal symptoms in people using medical Cannabis for chronic pain. Addiction, 2021, 116(8), 2067-2075. doi: 10.1111/add.15370 PMID: 33400332
  152. Russo, E.; Cannas, C.; Rivetti, M.S.; Villa, C.; Rebesco, B. Innovative clinical-organizational model to ensure appropriateness and quality in the management of medical Cannabis: An Italian Regional Case. Health care, 2021, 9(11), 1425.
  153. Onaivi, E.S.; Singh Chauhan, B.P.; Sharma, V. Challenges of cannabinoid delivery: How can nanomedicine help? Nanomedicine, 2020, 15(21), 2023-2028. doi: 10.2217/nnm-2020-0221 PMID: 32589080
  154. Ansari, M.A.; Badrealam, K.F.; Alam, A.; Tufail, S.; Khalique, G.; Equbal, M.J.; Alzohairy, M.A.; Almatroudi, A.; Alomary, M.N.; Pottoo, F.H. Recent nano-based therapeutic intervention of bioactive sesquiterpenes: Prospects in cancer therapeutics. Curr. Pharm. Des., 2020, 26(11), 1138-1144. doi: 10.2174/1381612826666200116151522 PMID: 31951164
  155. Esposito, E.; Ravani, L.; Drechsler, M.; Mariani, P.; Contado, C.; Ruokolainen, J.; Ratano, P.; Campolongo, P.; Trezza, V.; Nastruzzi, C.; Cortesi, R. Cannabinoid antagonist in nanostructured lipid carriers (NLCs): Design, characterization and in vivo study. Mater. Sci. Eng. C, 2015, 48, 328-336. doi: 10.1016/j.msec.2014.12.012 PMID: 25579930
  156. Esposito, E.; Drechsler, M.; Cortesi, R.; Nastruzzi, C. Encapsulation of cannabinoid drugs in nanostructured lipid carriers. Eur. J. Pharm. Biopharm., 2016, 102, 87-91. doi: 10.1016/j.ejpb.2016.03.005 PMID: 26952905
  157. Hassanzadeh, P.; Arbabi, E.; Atyabi, F.; Dinarvand, R. Carbon nanotube-anandamide complex exhibits sustained protective effects in an in vitro model of stroke. J. Physiol. Pharmacol., 2016, 20(1), 12-23.
  158. He, X.; Zhu, Y.; Wang, M.; Jing, G.; Zhu, R.; Wang, S. Antidepressant effects of curcumin and HU-211 coencapsulated solid lipid nanoparticles against corticosterone-induced cellular and animal models of major depression. Int. J. Nanomedicine, 2016, 11, 4975-4990. doi: 10.2147/IJN.S109088 PMID: 27757031
  159. Nakano, Y.; Tajima, M.; Sugiyama, E.; Sato, V.H.; Sato, H. Development of a novel nanoemulsion formulation to improve intestinal absorption of cannabidiol. Med. Cannabis Cannabinoids, 2019, 2(1), 35-42. doi: 10.1159/000497361 PMID: 34676332
  160. Chouhan, S.; Guleria, S. Green synthesis of AgNPs using Cannabis sativa leaf extract: Characterization, antibacterial, anti-yeast and α-amylase inhibitory activity. Mater. Sci. Energy Technol., 2020, 3, 536-544. doi: 10.1016/j.mset.2020.05.004
  161. Mandal, S.; Marpu, S.B.; Hughes, R.; Omary, M.A.; Shi, S.Q. Green synthesis of silver nanoparticles using Cannabis sativa extracts and their anti-bacterial activity. Green and Sustainable Chemistry, 2021, 11(1), 28-38. doi: 10.4236/gsc.2021.111004
  162. Csakvari, A.C.; Moisa, C.; Radu, D.G.; Olariu, L.M.; Lupitu, A.I.; Panda, A.O.; Pop, G.; Chambre, D.; Socoliuc, V.; Copolovici, L.; Copolovici, D.M. Green synthesis, characterization, and antibacterial properties of silver nanoparticles obtained by using diverse varieties of Cannabis sativa leaf extracts. Molecules, 2021, 26(13), 4041. doi: 10.3390/molecules26134041 PMID: 34279380
  163. Chang, Y.; Zheng, C.; Chinnathambi, A.; Alahmadi, T.A.; Alharbi, S.A. Cytotoxicity, anti-acute leukemia, and antioxidant properties of gold nanoparticles green-synthesized using Cannabis sativa L leaf aqueous extract. Arab. J. Chem., 2021, 14(4), 103060. doi: 10.1016/j.arabjc.2021.103060
  164. Levinsohn, E.A.; Hill, K.P. Clinical uses of Cannabis and cannabinoids in the United States. J. Neurol. Sci., 2020, 411, 116717. doi: 10.1016/j.jns.2020.116717 PMID: 32044684
  165. Okafor, C.N.; Plankey, M.W.; Goodman-Meza, D.; Li, M.; Bautista, K.J.; Bolivar, H.; Phyllis, T.C.; Brown, T.T.; Shoptaw, S.J. Association between self-reported marijuana use and incident diabetes in women and men with and at risk for HIV. Drug Alcohol Depend., 2020, 209, 107935. doi: 10.1016/j.drugalcdep.2020.107935 PMID: 32109711
  166. O’Connor, S.M.; Lietzan, E. The surprising reach of FDA regulation of Cannabis, even after descheduling. Am. Univ. Law Rev., 2019, 68(3), 823-925. PMID: 30919712
  167. Russo, E.; Guy, G.W. A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med. Hypotheses, 2006, 66(2), 234-246. doi: 10.1016/j.mehy.2005.08.026 PMID: 16209908
  168. Van Gaal, L.F.; Rissanen, A.M.; Scheen, A.J.; Ziegler, O.; Rössner, S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet, 2005, 365(9468), 1389-1397. doi: 10.1016/S0140-6736(05)66374-X PMID: 15836887
  169. Specchio, N.; Pietrafusa, N.; Cross, H.J. Source of cannabinoids: What is available, what is used, and where does it come from? Epileptic Disord., 2020, 22(S1), 1-9.
  170. Abuhasira, R.; Shbiro, L.; Landschaft, Y. Medical use of Cannabis and cannabinoids containing products – Regulations in Europe and North America. Eur. J. Intern. Med., 2018, 49, 2-6. doi: 10.1016/j.ejim.2018.01.001 PMID: 29329891
  171. Freeman, T.P.; Hindocha, C.; Green, S.F.; Bloomfield, M.A.P. Medicinal use of Cannabis based products and cannabinoids. BMJ, 2019, 365, l1141. doi: 10.1136/bmj.l1141 PMID: 30948383
  172. MacCallum, C.A.; Russo, E.B. Practical considerations in medical Cannabis administration and dosing. Eur. J. Intern. Med., 2018, 49, 12-19. doi: 10.1016/j.ejim.2018.01.004 PMID: 29307505
  173. Goldenberg, M.; Reid, M.W.; IsHak, W.W.; Danovitch, I. The impact of Cannabis and cannabinoids for medical conditions on health-related quality of life: A systematic review and meta-analysis. Drug Alcohol Depend., 2017, 174, 80-90. doi: 10.1016/j.drugalcdep.2016.12.030 PMID: 28319753

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bentham Science Publishers, 2024